BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 18829568)

  • 1. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors.
    Yi JM; Tsai HC; Glöckner SC; Lin S; Ohm JE; Easwaran H; James CD; Costello JF; Riggins G; Eberhart CG; Laterra J; Vescovi AL; Ahuja N; Herman JG; Schuebel KE; Baylin SB
    Cancer Res; 2008 Oct; 68(19):8094-103. PubMed ID: 18829568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promoter hypomethylation regulates CD133 expression in human gliomas.
    Tabu K; Sasai K; Kimura T; Wang L; Aoyanagi E; Kohsaka S; Tanino M; Nishihara H; Tanaka S
    Cell Res; 2008 Oct; 18(10):1037-46. PubMed ID: 18679414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrvinium Targets CD133 in Human Glioblastoma Brain Tumor-Initiating Cells.
    Venugopal C; Hallett R; Vora P; Manoranjan B; Mahendram S; Qazi MA; McFarlane N; Subapanditha M; Nolte SM; Singh M; Bakhshinyan D; Garg N; Vijayakumar T; Lach B; Provias JP; Reddy K; Murty NK; Doble BW; Bhatia M; Hassell JA; Singh SK
    Clin Cancer Res; 2015 Dec; 21(23):5324-37. PubMed ID: 26152745
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.
    Baba T; Convery PA; Matsumura N; Whitaker RS; Kondoh E; Perry T; Huang Z; Bentley RC; Mori S; Fujii S; Marks JR; Berchuck A; Murphy SK
    Oncogene; 2009 Jan; 28(2):209-18. PubMed ID: 18836486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of the stem cell marker CD133 is independent of promoter hypermethylation in human epithelial differentiation and cancer.
    Pellacani D; Packer RJ; Frame FM; Oldridge EE; Berry PA; Labarthe MC; Stower MJ; Simms MS; Collins AT; Maitland NJ
    Mol Cancer; 2011 Jul; 10():94. PubMed ID: 21801380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles.
    Beier D; Hau P; Proescholdt M; Lohmeier A; Wischhusen J; Oefner PJ; Aigner L; Brawanski A; Bogdahn U; Beier CP
    Cancer Res; 2007 May; 67(9):4010-5. PubMed ID: 17483311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
    Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
    Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of invasive properties of CD133+ glioblastoma stem cells: a role for MT1-MMP in bioactive lysophospholipid signaling.
    Annabi B; Lachambre MP; Plouffe K; Sartelet H; Béliveau R
    Mol Carcinog; 2009 Oct; 48(10):910-9. PubMed ID: 19326372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulation of Prominin 1/CD133 expression in colorectal cancer by NSAIDs following short-term preoperative treatment.
    Lönnroth C; Andersson M; Nordgren S; Lundholm K
    Int J Oncol; 2012 Jul; 41(1):15-23. PubMed ID: 22552364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-translational modulation of CD133 expression during sodium butyrate-induced differentiation of HT29 human colon cancer cells: implications for its detection.
    Sgambato A; Puglisi MA; Errico F; Rafanelli F; Boninsegna A; Rettino A; Genovese G; Coco C; Gasbarrini A; Cittadini A
    J Cell Physiol; 2010 Jul; 224(1):234-41. PubMed ID: 20333645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of CD133 mRNA expression in 48 glioblastoma patients treated with concomitant radiochemotherapy: a prospective patient cohort at a single institution.
    Metellus P; Nanni-Metellus I; Delfino C; Colin C; Tchogandjian A; Coulibaly B; Fina F; Loundou A; Barrie M; Chinot O; Ouafik L; Figarella-Branger D
    Ann Surg Oncol; 2011 Oct; 18(10):2937-45. PubMed ID: 21479688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD66c is a novel marker for colorectal cancer stem cell isolation, and its silencing halts tumor growth in vivo.
    Gemei M; Mirabelli P; Di Noto R; Corbo C; Iaccarino A; Zamboli A; Troncone G; Galizia G; Lieto E; Del Vecchio L; Salvatore F
    Cancer; 2013 Feb; 119(4):729-38. PubMed ID: 23027178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter hypermethylation and loss of CD133 gene expression in colorectal cancers.
    Jeon YK; Kim SH; Choi SH; Kim KH; Yoo BC; Ku JL; Park JG
    World J Gastroenterol; 2010 Jul; 16(25):3153-60. PubMed ID: 20593500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.
    Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V
    Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of multidrug resistance genes in normal and cancer stem cells.
    Shervington A; Lu C
    Cancer Invest; 2008 Jun; 26(5):535-42. PubMed ID: 18568776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter methylation and silencing of the tissue factor pathway inhibitor-2 (TFPI-2), a gene encoding an inhibitor of matrix metalloproteinases in human glioma cells.
    Konduri SD; Srivenugopal KS; Yanamandra N; Dinh DH; Olivero WC; Gujrati M; Foster DC; Kisiel W; Ali-Osman F; Kondraganti S; Lakka SS; Rao JS
    Oncogene; 2003 Jul; 22(29):4509-16. PubMed ID: 12881707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Celecoxib and radioresistant glioblastoma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation.
    Ma HI; Chiou SH; Hueng DY; Tai LK; Huang PI; Kao CL; Chen YW; Sytwu HK
    J Neurosurg; 2011 Mar; 114(3):651-62. PubMed ID: 21054139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD133 is essential for glioblastoma stem cell maintenance.
    Brescia P; Ortensi B; Fornasari L; Levi D; Broggi G; Pelicci G
    Stem Cells; 2013 May; 31(5):857-69. PubMed ID: 23307586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116.
    Dittfeld C; Dietrich A; Peickert S; Hering S; Baumann M; Grade M; Ried T; Kunz-Schughart LA
    Radiother Oncol; 2009 Sep; 92(3):353-61. PubMed ID: 19699546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to hypoxia-induced, BNIP3-mediated cell death contributes to an increase in a CD133-positive cell population in human glioblastomas in vitro.
    Kahlert UD; Maciaczyk D; Dai F; Claus R; Firat E; Doostkam S; Bogiel T; Carro MS; Döbrössy M; Herold-Mende C; Niedermann G; Prinz M; Nikkhah G; Maciaczyk J
    J Neuropathol Exp Neurol; 2012 Dec; 71(12):1086-99. PubMed ID: 23147506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.